Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 196 results for sepsis

  1. Healthcare-associated infections (QS113)

    This quality standard covers preventing and controlling infections in hospitals and other secondary care settings that develop because of treatment or from being in a healthcare setting (healthcare-associated infections). It includes monitoring, responsibilities, and policies and procedures in secondary care organisations to reduce the risk of infection in patients, staff and visitors. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    11 February 2016
    View quality statements

    Sections for QS113

  2. TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

    Technology appraisal guidance
    Published
    1 February 2016
    View recommendations

    Sections for TA383

  3. Agitation and delirium:- What is the best way to control delirium, with or without agitation, in the dying person, without causing undue sedation and without shortening life?

    is important:- People who are entering the last days of life may develop sepsis, dehydration and various biochemical disorders which may...

    Research recommendation
    Published
    27 January 2016

  4. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Remsima, Inflectra), certolizumab pegol (Cimzia), golimumab (Simponi), tocilizumab (RoActemra) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried conventional DMARDs only but they have not worked.

    Technology appraisal guidance
    Published
    26 January 2016
    View recommendations

    Sections for TA375

  5. What is the impact and longer-term clinical outcomes of adding procalcitonin testing to standard clinical practice with protocol-driven care in the NHS, to guide the use of antibiotic treatment in children and adults presenting to the emergency department with respiratory tract infection?

    Comes from guidance Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive...

    Research recommendation
    Published
    15 January 2016

  6. What is the impact and longer-term clinical outcomes of adding procalcitonin testing to standard clinical practice with protocol-driven care in the NHS, to guide the use of antibiotic treatment in children having antibiotics for a suspected or proven infection in an intensive care unit?

    Comes from guidance Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive...

    Research recommendation
    Published
    12 January 2016

  7. What is the impact and longer-term clinical outcomes of adding procalcitonin testing to standard clinical practice with protocol-driven care in the NHS, to guide the use of antibiotic treatment in people with confirmed or highly suspected sepsis in intensive care units and in people with suspected bacterial infections presenting to the emergency department?

    use of antibiotic treatment in people with confirmed or highly suspected sepsis in intensive care units and in people with suspected...

    Research recommendation
    Published
    12 January 2016

  8. What is the impact and longer-term clinical outcomes of adding procalcitonin testing to standard clinical practice with protocol-driven care in the NHS, to guide the use of antibiotic treatment in adults presenting to the emergency department with exacerbations of chronic inflammatory respiratory conditions such as chronic obstructive pulmonary disease?

    Comes from guidance Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive...

    Research recommendation
    Published
    12 January 2016

  9. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015

  10. Care of dying adults in the last days of life (NG31)

    This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.

    NICE guideline
    Published
    16 December 2015
    View recommendations

    Sections for NG31

  11. Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the diagnostic accuracy of serial C-reactive protein testing to identify chorioamnionitis in women with P-PROM?

    birth). Effective treatment of infection is particularly important given that sepsis is a common direct cause of maternal death. There...

    Research recommendation
    Published
    11 December 2015

  12. Gallstone disease (QS104)

    This quality standard covers diagnosing and managing gallstones in adults. It also includes managing complications of gallstones, such as an inflamed or infected gallbladder (cholecystitis), blocked and infected bile ducts (cholangitis), and an inflamed pancreas (pancreatitis). It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    3 December 2015
    View quality statements

    Sections for QS104

  13. Procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay) (DG18)

    Evidence-based recommendations on procalcitonin testing for diagnosing and monitoring sepsis (ADVIA Centaur BRAHMS PCT assay, BRAHMS PCT Sensitive Kryptor assay, Elecsys BRAHMS PCT assay, LIAISON BRAHMS PCT assay and VIDAS BRAHMS PCT assay)

    Diagnostics guidance
    Published
    7 October 2015

    Sections for DG18

  14. Thermogard XP for therapeutic hypothermia after cardiac arrest (MIB37)

    NICE has developed a medtech innovation briefing (MIB) on Thermogard XP for therapeutic hypothermia after cardiac arrest

    Medtech innovation briefing
    Published
    9 September 2015

  15. i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)

    NICE has developed a medtech innovation briefing (MIB) on i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department

    Medtech innovation briefing
    Published
    9 September 2015